Latest Breaking News On - Sunrise 1 trial - Page 1 : comparemela.com

The intravesical chemotherapy delivery system TAR-200 provided sustained and durable responses in patients with Bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer.

Andrea necchiScientific instituteSalute raffaele universityBacillus calmette guVita salute raffaele universityRaffaele hospitalTar 200Patients with bacillus calmette guérin unresponsiveHigh risk non muscle invasive bladder cancerSunrise 1 trialIrccs san raffaele hospital and scientific institute